For HealthcareProfessionals

View Patient Site (opens in a new tab)

Proven safety in clinical trials

Across three Phase III clinical studies,1,2,3 Cingal demonstrated a strong and consistent safety profile, with no treatment-related serious adverse events and a tolerability profile in line with established hyaluronic acid and corticosteroid treatments.

Repeat Injection Data

Safety Profile at a Glance

  • No treatment-related serious adverse events across 3 Phase III studies
  • Low incidence of mild, transient local reactions
  • Safety profile consistent with established HA and corticosteroid injections
  • No new safety concerns in repeat-injection follow-up study (n=242)

Consistent safety across all three Phase III studies

Safety data from three independent Phase III studies (comparing Cingal against HA alone,1 TH alone,2 and saline3) provide a comprehensive and consistent safety picture.

ecg-heart

Zero Treatment-Related Serious Adverse Events

No treatment-related SAEs reported across all three Phase III clinical studies.

bandage

Low Incidence of Local Reactions

Any local reactions observed were mild and transient, consistent with the known profile for intra-articular injections.

shield-check

Profile Aligned with Established Components

Overall safety profile consistent with established HA and corticosteroid intra-articular injections across all three comparator arms.

Repeat injection safety: Cingal 13-02 follow-up study

The Cingal 13-024 open-label follow-up study was specifically designed to evaluate the safety of repeat injections in patients previously treated with Cingal, directly addressing one of the key clinical questions for long-term OA management.

  • Design Open label safety study
  • Patients enrolled 242
  • Population Previously treated with Cingal
  • Primary focus Adverse events & joint examination findings following repeat injection
  • Reference Data on File 13-024

The study evaluated adverse events and joint examination findings following a repeat Cingal injection in patients with prior Cingal exposure. Results confirmed the safety profile seen in the Phase III programme:

  • No new safety concerns identified

    The repeat injection study found no new safety concerns in patients receiving a second Cingal injection, confirming that the safety profile is maintained with repeat administration, an important consideration for patients requiring annual OA management.

  • Adverse events consistent with known HA and corticosteroid profiles

    Any adverse events observed were consistent with the known safety profiles of hyaluronic acid and corticosteroid intra-articular injections, providing reassurance for prescribers managing patients across multiple injection cycles.

Both components carry a long-established safety record

25+

Years of Clinical Use

Hyaluronic Acid Injections

Hyaluronic acid intra-articular injections have been used in clinical practice for over 25 years, establishing a well-understood tolerability and safety profile across a large patient population.

40+

Years of Clinical Use

Corticosteroid Injections

Corticosteroid intra-articular injections have been used for inflammation management in orthopaedic and rheumatological practice for over 40 years, one of the most extensively characterised procedures in musculoskeletal medicine.